In this concluding episode of a 30-day deep dive series on FDA drug development in cannabinoid and psychedelic spaces, the hosts reflect on their journey through regulatory frameworks, scientific concepts, and therapeutic applications. The discussion emphasizes the importance of spiral learning - building from fundamental concepts like FDA pathways and ICH guidelines to more complex topics in psychedelic science. They explore how these emerging therapies could transform mental healthcare, moving beyond symptom management to address root causes of suffering, while highlighting the critical balance between innovation and responsible development.